C2N Diagnostics says it further bolstered its role as a leader in advanced brain health diagnostics at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam. The presentations included information on the company’s pipeline product, PrecivityAD2, along with other Precivity-related analytes that are setting a new standard in blood biomarker innovation and diagnostic performance.
The company’s next-generation product, PrecivityAD2, due for imminent release. is designed to help healthcare providers determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD), by using proprietary mass spectrometry technology.
These developments occur as the National Institute on Aging and the Alzheimer’s Association look to update their diagnostic criteria to incorporate blood biomarkers for the first time so healthcare providers can use them to identify amyloid plaques in the brain, a hallmark indicator of Alzheimer’s disease. The workgroup is currently collecting feedback and suggestions about the draft guidelines.
C2N CEO Dr Joel Braunstein noted that the developments at AAIC occur along with the fact that Eisai used C2N’s assay in its clinical trial for the recently approved LEQEMBI for Alzheimer’s disease treatment. “These activities demonstrate C2N’s blood biomarkers have been principal blood biomarkers to demonstrate biological evidence of clinically-relevant disease modification with anti-amyloid therapeutic antibodies. This positioning will continue to grow and be very helpful as diagnostic guidelines reflect these innovations and recognise their availability for use in clinical care.
It’s a privilege for our biomarkers to be incorporated into landmark treatment studies that are changing how patients with early AD will be managed. We believe these data, combined with primary care data further bolster the company’s position as the preferred partner in brain health diagnostics to work alongside healthcare providers in improving patient care and to advance clinical research of new treatment options for patients.”
